Incyte Corporation is a biopharmaceutical company that discovers, develops, and commercializes drugs across oncology and inflammatory disease areas in multiple markets including the United States, Europe, Canada, and Japan. The company markets several approved therapies targeting blood cancers, lymphomas, and other conditions, such as treatments for myelofibrosis, chronic myeloid leukemia, and various lymphomas, along with drugs addressing graft-versus-host disease and Merkel cell carcinoma. Its pipeline includes investigational candidates for solid tumors, atopic dermatitis, and other indications, with partnerships involving major pharmaceutical companies like Novartis and Lilly.
1Y: 124.75 (+45.1%) · range 81.66–129.93
entry readiness 12 · NOT READY · exit proximity 0
Value area 90.08–118.99 · 11% of 120d volume overhead · clean runway
No source detections in the last 21 days.
none
IMPROVING · rank 12 · inflow
| Horizon | Return | MFE | State |
|---|---|---|---|
| 20d | -2.36% | +1.29% | 3/20d |
| 40d | -2.36% | +1.29% | 3/40d |